We totaled the salaries, stock options and bonuses awarded to various medtech CEOs to figure out who the highest paid chiefs were. And our top 10 list saw a few ups and downs over the past year. We'll hear from Conor Hale and Andrea Park as they discuss medtech's highest paid CEOs.
Also in this episode, we cover the week's biggest headlines including Theranos' COO's jail sentence, highlights from the American Society of Hematology annual meeting and an update on the Horizon Therapeutics bidding war.
To learn more about topics in this episode:
- Fierce JPM Week
- The top 10 highest-paid medtech CEOs
- Fierce Biotech's ASH 2022 Coverage
- Fierce Pharma's ASH 2022 Coverage
- Theranos' Sunny Balwani lands 13-year fraud sentence after ex-partner Elizabeth Holmes gets 11 years
- Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati
- FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
- Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war
- Sanofi started—and lost—$28B bidding war for Horizon. Is the company's M&A appetite still rumbling?
- AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk
"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.